Acasti Pharma placed under review by Mackie Research Capital

Jan 13 21:01 2020 Print This Article

Disappointing results for its lead product candidate CaPre have led Mackie research capital analyst André Uddin to place Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) under review. This morning, Acasti reported topline results for Trilogy 1 Phase Three trail of CaPre that saw the company miss the primary endpoint due to an unexplained […]

The post Acasti Pharma placed under review by Mackie Research Capital appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

I’m out.

In the course of healing the nation this week, a certain pathetic blog made some recommendations about our house lust. For example, there would be less of it, and far more attractive, affordable, long-term rental units, if we stopped giving people a 100% tax break on real estate profits. This is t ...

A quantitative retrospection in a qualitative world - Loonie Politics

  The Samara Centre for Democracy released their retrospective on the 42nd Parliament this week, titled House Inspection, and it takes a look back at how the last parliament behaved on a number of metrics.  It’s important research to do, but I’m going to quibble with some of their methodolog ...

Trudeau doesn’t know what “normal” is - Loonie Politics

  Apparently we’re manufacturing a scandal here with Trudeau’s posh doughnuts.  At least so says a National Post colleague.  But putting aside that we journalists would never hyperventilate salaciously over trivia, it seems to me it’s the PM who manufactured the scandal. When I first saw ...

Show trials in Washington and Guantanamo Bay repress justice

US Politics All eyes are on the U.S. Senate this week for the impeachment trial of President Donald J. Trump, only the third presidential impeachment trial in U.S. history. But another important trial is happening at the same time, far from the eyes of the public, at the U.S. naval base at Guanta ...

The Ten Best Performing Canadian Life Sciences Stocks of 2019

It was another up and down year for Canadian Life Sciences stocks. In 2018, the downfall of the sector came in the last couple of months. A year later, it happened early when cannabis stocks began to collapse. (The S&P TSX Pharma & Biotech Index lost almost half of its value between March and the [ ...

Acasti Pharma placed under review by Mackie Research Capital

Disappointing results for its lead product candidate CaPre have led Mackie research capital analyst André Uddin to place Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) under review. This morning, Acasti reported topline results for Trilogy 1 Phase Three trail of CaPre that saw th ...

Tech Talk for Thursday January 9th 2020

Pre-opening Comments for Thursday January 9th U.S. equity index futures were higher this morning. S&P 500 futures were up 11 points in pre-opening trade. Index futures were virtually unchanged following release of Weekly Initial Jobless Claims at 8:30 AM EST. Consensus was unchanged from the previo ...

Acasti Pharma keeps “Top Pick” Status at Echelon for 2020

Quebec-based omega-3 drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) is keeping its “Top Pick” status from Echelon Wealth Partners analyst Douglas Loe. In a research update to clients Tuesday, Loe maintained his “Speculative Buy” rating and $4.00 price target ...

Canopy Growth will remain a problem for Constellation Brands, this investor says

The write-downs likely aren’t done yet. That’s the takeaway from portfolio manager Jason Mann’s assessment of Constellation Brands (Constellation Brands Stock Quote, Chart, News NYSE:STZ) and its troubled investment in cannabis company Canopy Growth (Canopy Growth Stock Quote, Chart, News TSX ...

The worst is over for Organigram, says Raymond James

Operational excellence was the takeaway from Organigram Holdings (Organigram Holdings Stock Quote, Chart, News TSX:OGI) in its latest quarter, according to Raymond James analyst Rahul Sarugaser, who in an update to clients on Wednesday raised his rating for OGI from “Market Perform 3” to “Out ...

PI Financial cuts price target on Aphria

Following the company’s second quarter results, PI Financial analyst Jason Zandberg has cut his price target on Aphria (Aphria Stock Quote, Chart, News TSX:APHA), though the analyst has maintained his “Buy” rating on the stock. On Tuesday, Aphria reported its Q2, 2020 results. The company los ...